18F-FDG kinetics and gene expression in giant cell tumors

Journal of Nuclear Medicine

Volumn 45, Issue 9, 2004, Pages 1528-1535

  Strauss, Ludwig G ^a   Dimitrakopoulou Strauss, Antonia ^a   Koczan, Dirk ^b   Bernd, Ludger ^c   Haberkorn, Uwe ^a   Ewerbeck, Volker ^c   Thiesen, Hans Jürgen ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

18F FDG; Gene expression; Giant cell tumor; Quantification

Indexed keywords

BETA 2 MICROGLOBULIN; BIGLYCAN; CELL CYCLE PROTEIN; CELL DIVISION CYCLE PROTEIN 2; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG; VASCULOTROPIN A; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER; TUMOR PROTEIN;

ANGIOGENESIS; ARTICLE; BONE CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KINETICS; NUCLEOTIDE SEQUENCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS MODEL; QUANTITATIVE ANALYSIS; SOFT TISSUE SARCOMA; TUMOR VOLUME; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; STATISTICS; VALIDATION STUDY;

FLUORODEOXYGLUCOSE F18; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GIANT CELL TUMORS; HUMANS; KINETICS; METABOLIC CLEARANCE RATE; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RADIOPHARMACEUTICALS; STATISTICS; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 6944219756     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Tubbs WS, Brown LR, Beabout JW, Rock MG, Unni KK. Benign giant-cell tumor of bone with pulmonary metastases: clinical findings and radiologic appearance of metastases in 13 cases. AJR. 1992;158:331-334.
2. Tian BL, Wen JM, Zhang M, Xie D, Xu RB, Luo CJ. The expression of ADAM12 (meltrin alpha) in human giant cell tumours of bone. Mol Pathol. 2002;55:394-397.
3. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol. 2002;117:210-216.
4. Kumta SM, Huang L, Cheng YY, Chow LTC, Lee KM, Zheng MH. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci. 2003;73:1427-1436.
5. Dimitrakopoulou-Strauss A, Strauss LG, Koczan D, Thiesen HJ, Bernd L, Haberkorn U. FDG kinetics and association with cyclin-A and vascular endothelial growth factor [abstract]. J Nucl Med. 2003;44(suppl):80P.
6. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, et al. Glucose transporters and hexokinases: correlation with FDG kinetics and coexpression with other genes [abstract]. J Nucl Med. 2003;44(suppl):80P.
7. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623-648.
8. Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med. 1997;38:1818-1823.
9. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A Java environment for medical image data analysis: initial application for brain PET quantitation. Med Inform. 1998;23:207-214.
10. 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods. 1993;50:263-272.
11. Sokoloff L, Smith CB. Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Widén L, eds. The Metabolism of the Human Brain Studied with Positron Emission Tomography. New York, NY: Raven Press; 1983:123-148.
12. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med. 1991;32:1432-1438.
13. Teague TK, Hildeman D, Kedl RM, et al. Activation changes the spectrum but not the diversity of genes expressed by T cells. Proc Natl Acad Sci USA. 1999;96:12691-12696.
14. 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med. 2001;42:713-720.
15. Waddington RJ, Roberts HC, Sugars RV, Schönherr E. Differential roles for small leucine-rich proteoglycans in bone formation. Eur Cell Mater. 2003;6:12-21.
16. Menessen HD, Siehl JM, Thiel E. Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol. 2002;76:103-109.
17. Yoshioka K, Nakamori S, Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res. 1999;59:2004-2010.
18. Kamai T, Tsujii T, Arai K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003;9:2632-2641.
19. Jelinek JS, Murphey MD, Welker JA, et al. Diagnosis of primary bone tumors with image-guided percutaneous biopsy: experience with 110 tumors. Radiology. 2002;223:731-737.
20. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med. 1988;29:181-186.
21. 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med. 2002;43:510-516.
22. Wu H, Dimitrakopoulou-Strauss A, Heichel TO, et al. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis. Eur J Nucl Med. 2001;28:704-710.
23. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake values in 52 lesions. Radiology. 2001;219:774-777.
24. Ito S, Fukusato T, Nemoto T, Sekihara H, Seyama Y, Kubota S. Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst. 2002;94:1080-1091.
25. Pedersen MWB, Holm S, Lund EL, Højgaard L, Kristjansen PEG. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SLC) sublines in vivo and in vitro. Neoplasia. 2001;3:80-87.
26. Burke B, Giannoudis A, Corke KP, et al. Hypoxia-induced gene expression in human macrophages. Am J Pathol. 2003;163:1233-1243.
27. Inoue T, Kibata K, Suzuki M, Nakamura S, Motoda R, Orita K. Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt-1, from a human hematopoietic cell line NALM-16. FEBS Lett. 2000;469:14-18.
28. Takahashi R, Tanaka S, Kitadai Y, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology. 2003;64:266-274.
29. Zheng MH, Xu J, Robbins P, et al. Gene expression of vascular endothelial growth factor in giant cell tumors of bone. Hum Pathol. 2000;31:804-812.
30. Shijubo N, Kojima H, Nagata M, et al. Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech. 2003;60:186-198.
31. Marion-Audibert AM, Barel C, Gouysse G, et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology. 2003;125:1094-1104.
32. Sulh MA, Greco MA, Jiang T, Goswami SB, Present D, Steiner G. Proliferation index and vascular density of giant cell tumors of bone: are they prognostic markers? Cancer. 1996;15:2044-2051.
33. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA. 1988;95:11709-11714.
34. Silvestre JS, Tamarat R, Ebrahimian TG, et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res. 2003;93:114-123.